Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Gerresheimer Aktie 3138496 / DE000A0LD6E6

01.10.2025 13:00:03

EQS-News: Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials

EQS-News: Gerresheimer AG / Key word(s): Expansion
Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials

01.10.2025 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials

  • New production hall for RTF vials and innovative EZ-fill Smart packaging platform
  • Best possible protection for sensitive biologics
  • Total investment volume of around EUR 30 million
  • Around 50 new jobs for skilled workers from the region

Düsseldorf/Wertheim, Germany, October 1, 2025. Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has officially started construction of a new production facility at its Wertheim site, Germany with a groundbreaking ceremony. By mid 2027, high-quality ready-to-fill (RTF/RTU) vials are expected to roll off the production line in a new 4,000 m² production hall in the innovative EZ-fill Smart packaging platform. At its Wertheim site, Gerresheimer employs around 160 people to produce injection vials and ampoules. The planned expansion is expected to create a further 50 jobs for skilled workers from the region. Wertheim will be the second Gerresheimer production site, alongside Querétaro, Mexico, to offer RTF vials in the innovative EZ-fill Smart packaging platform. Gerresheimer is investing a total of around EUR 30 million in the construction and technical equipment of the new production building. The expansion underlines Gerresheimer’s position as a leading system and solution provider to the pharma and biotech industry, especially for injectable biopharmaceuticals.

“The expansion in Wertheim is an example of how we are implementing our growth strategy by expanding our portfolio with specialized systems and solutions for biopharmaceuticals,” explains Dietmar Siemssen, CEO of Gerresheimer AG.

“EZ-fill Smart is the next-generation packaging platform for ready-to-fill vials. Together with our Gx Elite RTF Vials, this high-value solution delivers optimal product quality and the best possible protection for sensitive biopharmaceuticals”, adds Volker Rekowski, Senior Vice President Europe & Asia Tubular Glass at Gerresheimer.

Center of excellence for vials and ampoules

The Wertheim site, which has been producing pharmaceutical ampoules since 1957, has been part of the Gerresheimer Group since 1989. It is Gerresheimer’s European Center of Excellence for high-value Gx Elite vials and ampoules, and in the future also for pre-sterilized “ready-to-fill” (RTF) vials. The last investment at the site was made in 2022 in new production lines for Gx Elite vials. The injection vials of the “Elite” performance level are characterized by very high break resistance, precisely maintained tolerances, and maximum surface quality. After about two years of planning, a state-of-the-art production infrastructure for RTF/RTU vials is now being built in Wertheim. The RTF/RTU vial market is expected to grow at a compound annual growth rate of around 13% until 20301.

EZ-fill Smart for best possible protection and efficient filling

With the new production hall, the Gx Elite Vials manufactured at the Wertheim Site will also be available as pre-sterilized “ready-to-fill” (RTF/RTU) versions in the EZ-fill Smart packaging platform. EZ-fill Smart is the next-generation packaging platform for RTF vials. Advantages include even less particles and, in the future, the possibility to use vaporized hydrogen peroxide (VHP) as an alternative, environmentally friendly and resource-saving sterilization method. EZ-fill Smart is compatible with all standard fill & finish lines, enabling flexible, safe, and cost-efficient filling processes. Combined with Gx Elite vials, EZ-fill Smart ensures highest protection for sensitive and expensive drugs such as novel biologics.

GMP Class C cleanroom

The RTF processing and packaging of the vials in the EZ-fill Smart format is planned to take place in the new production hall in an approximately 800 m² GMP Class C clean room (GMP = Good Manufacturing Practice). The new production infrastructure will thus meet the highest pharmaceutical requirements, as specified, for example, in Annex 1 of the EU GMP guidelines for the manufacture of sterile medicinal products in the EU.

Energy efficiency and sustainability

The planned new building combines energy efficiency and sustainability in both construction and its technical systems. A 175 kWp photovoltaic system will be installed on the roof of the new building, with the remaining surface being greened. The entire power supply will come from 100% renewable sources.

Around 50 new jobs for professionals from the region

In the first expansion phase, around 50 new jobs for skilled workers from the region will be created by 2028. The production capacity for RTF/RTU vials in the new production hall can be further increased in the coming years.


1Prescient & Strategic Intelligence: Global RTF/RTU Vials Market (CAGR 14.5% 2021 to 2030) and Gerresheimer estimate

 

About Gerresheimer 
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,600 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).    
www.gerresheimer.com 
 

Contact Gerresheimer AG

Media  
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264
jutta.lorberg@gerresheimer.com                          
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 172 2424185
marion.stolzenwald@gerresheimer.com


01.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Gerresheimer AG
Peter-Müller-Str. 3
40468 Duesseldorf
Germany
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-121
E-mail: gerresheimer.ir@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2206858

 
End of News EQS News Service

2206858  01.10.2025 CET/CEST

Analysen zu Gerresheimer AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
28.10.25 Gerresheimer Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
21.10.25 Gerresheimer Buy Jefferies & Company Inc.
15.10.25 Gerresheimer Hold Hauck Aufhäuser Lampe Privatbank AG
14.10.25 Gerresheimer Neutral UBS AG
13.10.25 Gerresheimer Overweight JP Morgan Chase & Co.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Kommt 2025 der grosse KI-Crash? Tim Schäfer über Nvidia, OpenAI & die Parallelen zu 1929

Könnte der aktuelle KI-Boom an den Börsen in einen Crash münden – ähnlich wie 1929 oder zur Dotcom-Blase? 📉💻

In diesem spannenden Gespräch mit Tim Schäfer sprechen wir über Parallelen zum historischen Börsencrash, die massive Überbewertung vieler Tech- und KI-Aktien wie Nvidia, Palantir oder Microsoft – und was das für Langfristanleger bedeutet. Ist der Hype finanziell überhaupt noch tragbar? Wie positionieren sich Insider und Grossinvestoren wie Warren Buffett oder Peter Thiel?

💬 Welche Risiken birgt der aktuelle KI-Hype?
💬 Was sagen Insiderverkäufe und Bewertungen über die Marktlage?
💬 Wie sollte man sich als Privatanleger jetzt aufstellen?

Ein Interview für alle, die sich fragen: Ist das noch Wachstum oder schon Wahnsinn?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Kommt 2025 der grosse KI-Crash? Tim Schäfer über Nvidia, OpenAI & die Parallelen zu 1929

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’123.92 19.91 SRVB3U
Short 13’395.97 13.78 S0IB1U
Short 13’916.84 8.74 S83BOU
SMI-Kurs: 12’632.67 21.11.2025 17:30:12
Long 12’098.54 19.60 SPMB5U
Long 11’821.61 13.71 SQBBAU
Long 11’328.91 8.93 SEPBTU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel